<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:28923694;
mso-list-template-ids:-1359726176;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:152917145;
mso-list-template-ids:-1888465112;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:186482392;
mso-list-template-ids:-264980306;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:397824009;
mso-list-template-ids:1875822644;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:539443814;
mso-list-template-ids:750798160;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:1256673509;
mso-list-template-ids:994374194;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;color:#1F497D">The last one of 2020! Happy Holidays!<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/grants__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdlV4L_34$" target="_blank">William T. Grant Foundation: Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">We fund research that increases understanding in one of our two focus areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">programs, policies, and practices that
<a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/reducing-inequality__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdIo9gjXA$">reduce inequality</a> in youth outcomes, and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">strategies to
<a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/improving-use-research-evidence__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdElwxV70$">
improve the use of research evidence</a> in ways that benefit youth.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The <b>Reducing Inequality program</b> supports high-quality field-initiated studies from a range of disciplines and methodologies that are relevant to policies and practices that affect
the lives of young people between the ages of 5 and 25 in the United States. Through the program, grants of up to $600,000 over a period of up to three years will be awarded in support of major research designed to build, test, or increase understanding of
programs, policies, or practices with the potential to reduce inequality in the academic, social, behavioral, or economic outcomes of young people. Descriptive studies that clarify mechanisms for reducing inequality or elucidate how or why a specific program,
policy, or practice operates to reduce inequality are welcomed. The foundation prioritizes studies about reducing inequality on the basis of race, ethnicity, economic standing, language, minority status, or immigrant origin. It also welcomes studies from a
range of disciplines, fields, and methodologies and encourages investigations into various systems, including justice, housing, child welfare, mental health, and education. Competitive proposals often incorporate data from multiple sources and often involve
multidisciplinary teams. In addition to financial support, grantees receive significant time and capacity-building resources from the foundation. Projects led by African American, Latinx, Native American, and Asian Pacific American researchers are encouraged.
The <b>Improving the Use of Research Evidence program</b> supports high-quality field-initiated studies that identify, build, and test strategies to enhance the use of research evidence in ways that benefit youth (ages 5 to 25 in the US). We are particularly
interested in research on improving the use of research evidence by state and local decision makers, mid-level managers, and intermediaries. Some investigators will focus on the strategies, relationships, and other supports needed for policy and practice organizations
to use research more routinely and constructively. Others may investigate structures and incentives within the research community to encourage deep engagement with decision makers. Still other researchers may examine activities that help findings inform policy
ideas, shape practice responses, and improve systems.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letters of inquiry to either program due January 13, 2021; May 5, 2021; August 4, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for January due date: January 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdKcJBcCU$" target="_blank">Alzheimer’s Drug Discovery Foundation: Program to Accelerate Clinical Trials (PACT)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias.
Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted
approaches and cholinesterase inhibitor proposals will not be considered for this RFP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Stage of development:</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">1. Early-stage human clinical trials including:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Phase 0 micro- or sub-therapeutic-dosing studies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Phase 1 trials in healthy subjects<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Biomarker-based proof-of-concept studies (generally phase 1b or phase 2a trials) designed to assess target engagement and downstream pharmacologic effects<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">2. Regulatory studies including:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial
authorization (CTA) preclinical packages. Funding is available for preparation of traditional and exploratory IND applications<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Long-term toxicology studies to enable longer-term dosing in phase 2 trials<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials<o:p></o:p></span></li></ul>
<p class="MsoNormal"><i><span style="font-size:12.0pt;font-family:Palatino">For clinical trial applications, if IND-enabling work is in progress, funding for clinical studies would be contingent upon an IND (or equivalent) being granted and full review of the
data package. </span></i><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Type of therapy:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered.
Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Drug mechanisms or modes of action:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Novel drug mechanisms and modes of action related to the biology of aging and other
emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Epigenetics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Mitochondrial & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Proteostasis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Vascular function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">Please note:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines,
beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Average Duration:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Varies<br>
<b>Average Award:</b> Up to $3 million; no IDC<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due February 5, 2021; May 28, 2021; October 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for February due date: January 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 and R61 / R33 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-097.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAduh7fpQI$" target="_blank">R34</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-098.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdn6v3Sqo$" target="_blank">R61 / R33</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of these FOAs
is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via these mechanisms will consist of studies that are a pre-requisite
for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 19, 2021; June 17, 2021; October 19, 2021; February 17, 2022; June, 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; and October 17, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 2021 due date: February 8.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-117.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdbhJapS0$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-116.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAd6CEKLm8$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial, and structural
factors contributing to mood disorders in people living with HIV. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 10, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: February 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21543/nsf21543.htm__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdmKC6au0$" target="_blank">NSF Integrative Research in Biology (IntBIO)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Integrative Research in Biology program replaces the Rules of Life track. This solicitation invites submission of collaborative proposals that tackle bold questions in biology and
require an integrated approach to make substantive progress. Integrative biological research spans subdisciplines and incorporates cutting-edge methods, tools, and concepts from each to produce groundbreaking biological discovery. The research should be synergistic
and produce novel, holistic understanding of how biological systems function and interact across different scales of organization, e.g., from molecules to cells, tissues to organisms, species to ecosystems and the entire Earth. Such knowledge is critical to
inform solutions to societal challenges, including natural resource management, resilience to environmental change, and global food security. Outcomes from integrative research will also inform and guide the development of new technologies that drive the nation’s
bioeconomy.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 16, 2021 and January 25, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for March due date: March 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21546/nsf21546.htm__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdjgL62Eg$" target="_blank">Enabling Discovery through GEnomic Tools (EDGE)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through the Enabling Discovery through GEnomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding
of comparative and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and
phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals
are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype,. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and
phenotypes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The EDGE program will accept proposals to two submission tracks:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FUNCTIONAL GENOMIC TOOLS (FGT) TRACK</span></b><span style="font-size:12.0pt;font-family:Palatino">: Proposals submitted to this track should aim to develop and provide proof-of-concept
tests of functional genomic tools and infrastructure to enable direct tests of hypotheses about gene function in diverse species for which such tools and infrastructure are presently unavailable. Investigators may use taxonomic, question-based, and/or technology-based
strategies to develop tools and approaches that will be employed by larger communities of researchers. Projects may include instrumentation development followed by proof-of-concept testing in the context of developing functional genomic tools to enable direct
tests of gene function. Examples of relevant objectives for plants, animals, microbes, viruses, or fungi for which such tools and infrastructure are presently unavailable include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Development of mutant libraries and/or high-quality reference genomes;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Expansion of the use of gene editing, knock-out, and overexpression approaches for manipulating individual genes or interrogating multiple genes simultaneously
in diverse organisms;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Development of approaches to test gene function in a variety of targeted, single cells in organisms;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Generalizable high-throughput phenotyping methods;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Innovative approaches for establishing function of single or networks of genes; and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Development and testing of transformation approaches.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">COMPLEX MULTIGENIC TRAITS (CMT) TRACK:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Proposals submitted to this track should include hypothesis-driven research that
advances understanding of the relationship between genomes and complex multi-genic traits, toward the goal of predicting phenotypes across diverse contexts, including environmental, developmental, social, and/or genomic contexts. Successful proposals may include
the development of theory and/or analytical approaches to achieve the scientific goal. The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding
complex traits requires systems-level analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to the COMPLEX MULTIGENIC TRAITS TRACK should emphasize the contribution of genome-wide factors
that impact expression of a phenotype.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Submissions to this track may include but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Systems-level analysis of the gene regulatory networks underlying complex traits;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Elucidation of the causal connections across levels of biological organization that underlie complex multigenic traits;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">New or innovative analytical approaches to linking genes and complex traits; and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Multi-genome/epigenome interactions with the environment towards the goal of predicting complex organismal phenotypes across contexts.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Budget requests should be commensurate with the goals of the project. The EDGE program expects to make awards covering the full range of budget requests commensurate with the size and
scope of each project.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals accepted anytime.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-002.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdIXuLXOY$" target="_blank">Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal
models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-001.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdBQN7DAw$" target="_blank">New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research
Exploration (ASPIRE) Collaborative Research Program (UG3 / UH3 Clinical Trials Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop
approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural
scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA
will support intramural – extramural collaborations to develop additional physical modules that will enhance the platform’s capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting
points for drug development of novel targets, and the expansion of chemical space available for drug screening.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
</div>
</body>
</html>